⚠️FOR RESEARCH PURPOSES ONLY
← Back to Research Database
ResearchPeptide

Cagrilintide

Published Research

PubMed-indexed studies for Cagrilintide

Research

Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.

Cardiology in review 2024
View on PubMed →
Research

Development of Cagrilintide, a Long-Acting Amylin Analogue.

Journal of medicinal chemistry 2021
View on PubMed →
Research

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.

Lancet (London, England) 2021
View on PubMed →
Research

Amylin analogs for the treatment of obesity without diabetes: present and future.

Expert review of clinical pharmacology 2024
View on PubMed →
Research

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.

Lancet (London, England) 2023
View on PubMed →
Research

Drugs for Treating Obesity.

Handbook of experimental pharmacology 2022
View on PubMed →

Research-Grade Cagrilintide

YPB.241
Cagrilintide (10mg)
$110.00
⚠️ For laboratory research only. Not for human use.